Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.
Cutaneous Allergy, St John's Institute of Dermatology, St Thomas' Hospital, London, SE1 7EH, UK.
A C
AC
Kai
C
C
Flohr
C E
CE
Grattan
D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D000069444:Omalizumab; D011788:Quality of Life; D012008:Recurrence; D012189:Retrospective Studies; D014581:Urticaria / Q000188:drug therapy*; D014657:Vasculitis / Q000188:drug therapy*
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab